|
|
|
International Clinical Trials
|
Acceleration of the integration of mobile health (mHealth) technologies into clinical trial operations is expected to be the catalyst for the adoption of disruptive research platforms with capabilities to overcome barriers in both clinically mature and emerging markets. While mHealth applications of smart devices, wearable biometric sensors, and telemedicine enable health monitoring, data collection, and patient communications have been around for some time. Despite this, their widespread use in clinical research should still be considered in its infancy. We continue to see the fast development of integrated mHealth platforms that have the potential to turn the traditional research model on its head – taking studies to patients rather than bringing patients into site-based studies. Powered by Big Data and connected across patients, researchers, and caregivers, emerging mHealth platforms will expand research participation, reduce costs, and integrate research with treatment in new models of personalised medicine based on real-world evidence.
The mHealth Disruption Four foundational trends are driving 21st century biomedical research:
- Globalisation is expanding drug development into the emerging markets of Africa, Asia, and Latin America
- Big Data is being harnessed to understand disease impacts at the population level and support evidence-based medical practice
- Real-world evaluation is extending the continuum from traditional randomised clinical trials to new research models that assess real-world outcomes
- Personalised medicine is advancing with targeted therapies tailored to smaller populations and the growth of patientcentric research
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
News and Press Releases |
 |
Phenomenex Introduces bioZen Series for Characterization of Biotherapeutics
Torrance, Calif. (April 16, 2018) – Phenomenex Inc., a global leader in
the research and manufacture of advanced technologies for the separation
sciences, introduces bioZen – a new series of LC solutions for bioseparations
in pharmaceutical, biopharmaceutical and academic research. The series
encompasses both proven and entirely new media spanning two particle platforms
– core-shell and thermally modified fully porous – along with new biocompatible
titanium hardware. The initial bioZen product line features seven chemistries
for the UHPLC and HPLC characterization of biotherapeutics such as monoclonal
antibodies, antibody-drug conjugates and biosimilars. The offering includes
specific LC chemistries for the analysis of aggregates and total mAb, intact
mass and fragments, peptide mapping and quantitation and glycan mapping.
More info >> |
|
 |
White Papers |
 |
|
Digital Transformation of the Cold Chain
Sensitech EMEA
The Life Sciences cold chain is a seamless and interconnected global network of people, equipment, data and processes that helps to ensure the safety and integrity of our medicines and vaccines. Cold chain logistics spending totaled $13 billion in 2017, an investment designed to protect some $283 billion in Life Sciences cold chain products, growing at 19% annually.1 Sensitech Inc., a part of UTC Climate, Controls & Security, a unit of United Technology Corp., has played an essential part in the Life Sciences cold chain since 1990, providing a comprehensive set of solutions for manufacturers of biologics, prescription pharmaceuticals, clinical trial materials, and over-the-counter drugs. These solutions help to ensure product quality, patient safety, and regulatory compliance while helping to prevent theft and optimizing cold chain performance.
More info >> |
|
 |
Industry Events |
 |
SMI Immuno-Oncology Conference
25-27 September 2018, Copthorne Tara Hotel, London, UK
Immuno-Oncology is a fast-paced field with massive potential to deliver
successful and durable cancer therapies, and SMi's Immuno-Oncology Conference will focus on a few key areas of
the field with a representation of the whole industry under each area. These
areas will be drawn together to look towards the future of Immuno-oncology and
how the field can progress.
More info >> |
|
|
